Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus: caveat emptor.
Ramsey
Keith M
KM
Mazer
Mark A
MA
D003422:Critical Care / Q000379:methods; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification*; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D011379:Prognosis; D012293:Rifampin / Q000008:administration & dosage*; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage*
D014640:Vancomycin; D012293:Rifampin